193 related articles for article (PubMed ID: 36315921)
1. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
Jelinek T; Bezdekova R; Zihala D; Sevcikova T; Anilkumar Sithara A; Pospisilova L; Sevcikova S; Polackova P; Stork M; Knechtova Z; Venglar O; Kapustova V; Popkova T; Muronova L; Chyra Z; Hrdinka M; Simicek M; Garcés JJ; Puig N; Cedena MT; Jurczyszyn A; Castillo JJ; Penka M; Radocha J; Mateos MV; San-Miguel JF; Paiva B; Pour L; Rihova L; Hajek R
J Clin Oncol; 2023 Mar; 41(7):1383-1392. PubMed ID: 36315921
[TBL] [Abstract][Full Text] [Related]
2. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
van de Donk NWCJ
J Clin Oncol; 2023 Mar; 41(7):1342-1349. PubMed ID: 36450104
[No Abstract] [Full Text] [Related]
3. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
Hofste Op Bruinink D; Kuiper R; van Duin M; Cupedo T; van der Velden VHJ; Hoogenboezem R; van der Holt B; Beverloo HB; Valent ET; Vermeulen M; Gay F; Broijl A; Avet-Loiseau H; Munshi NC; Musto P; Moreau P; Zweegman S; van de Donk NWCJ; Sonneveld P
J Clin Oncol; 2022 Sep; 40(27):3132-3150. PubMed ID: 35357885
[TBL] [Abstract][Full Text] [Related]
4. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Bertamini L; Oliva S; Rota-Scalabrini D; Paris L; Morè S; Corradini P; Ledda A; Gentile M; De Sabbata G; Pietrantuono G; Pascarella A; Tosi P; Curci P; Gilestro M; Capra A; Galieni P; Pisani F; Annibali O; Monaco F; Liberati AM; Palmieri S; Luppi M; Zambello R; Fazio F; Belotti A; Tacchetti P; Musto P; Boccadoro M; Gay F
J Clin Oncol; 2022 Sep; 40(27):3120-3131. PubMed ID: 35666982
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Garcés JJ; Cedena MT; Puig N; Burgos L; Perez JJ; Cordon L; Flores-Montero J; Sanoja-Flores L; Calasanz MJ; Ortiol A; Blanchard MJ; Rios R; Martin J; Martínez-Martinez R; Bargay J; Sureda A; de la Rubia J; Hernandez MT; Rodriguez-Otero P; de la Cruz J; Orfao A; Mateos MV; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; San-Miguel JF; Paiva B
J Clin Oncol; 2022 Sep; 40(27):3151-3161. PubMed ID: 35666958
[TBL] [Abstract][Full Text] [Related]
6. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Fernández de Larrea C; Kyle R; Rosiñol L; Paiva B; Engelhardt M; Usmani S; Caers J; Gonsalves W; Schjesvold F; Merlini G; Lentzch S; Ocio E; Garderet L; Moreau P; Sonneveld P; Badros A; Gahrton G; Goldschmidt H; Tuchman S; Einsele H; Durie B; Wirk B; Musto P; Hayden P; Kaiser M; Miguel JS; Bladé J; Rajkumar SV; Mateos MV
Blood Cancer J; 2021 Dec; 11(12):192. PubMed ID: 34857730
[TBL] [Abstract][Full Text] [Related]
7. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
Bezdekova R; Jelinek T; Kralova R; Stork M; Polackova P; Vsianska P; Brozova L; Jarkovsky J; Almasi M; Boichuk I; Knechtova Z; Penka M; Pour L; Sevcikova S; Hajek R; Rihova L
Br J Haematol; 2021 Oct; 195(1):95-107. PubMed ID: 34500493
[TBL] [Abstract][Full Text] [Related]
8. Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma.
Kostopoulos IV; Ntanasis-Stathopoulos I; Rousakis P; Malandrakis P; Panteli C; Eleutherakis-Papaiakovou E; Angelis N; Spiliopoulou V; Syrigou RE; Bakouros P; Dimitrakopoulou G; Fotiou D; Migkou M; Kanellias N; Paschalidis N; Gavriatopoulou M; Kastritis E; Dimopoulos MA; Tsitsilonis OE; Terpos E
Am J Hematol; 2024 Jun; ():. PubMed ID: 38860642
[TBL] [Abstract][Full Text] [Related]
9. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Haematologica; 2017 Aug; 102(8):1439-1445. PubMed ID: 28473618
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
[TBL] [Abstract][Full Text] [Related]
14. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.
Paiva B; Paino T; Sayagues JM; Garayoa M; San-Segundo L; Martín M; Mota I; Sanchez ML; Bárcena P; Aires-Mejia I; Corchete L; Jimenez C; Garcia-Sanz R; Gutierrez NC; Ocio EM; Mateos MV; Vidriales MB; Orfao A; San Miguel JF
Blood; 2013 Nov; 122(22):3591-8. PubMed ID: 24072855
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell leukemia: from biology to treatment.
Jelinek T; Kryukov F; Rihova L; Hajek R
Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
Jimenez-Zepeda VH; Dominguez-Martinez VJ
Int J Hematol; 2009 Apr; 89(3):259-268. PubMed ID: 19326058
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
18. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]